Publications by authors named "Audrey Menard"
Article Synopsis
- * Researchers used genomic and RNA-sequencing analyses to find that subclones of resistant cancer cells develop mutations (like CARD11) that enable them to evade the therapies by enhancing specific survival genes, contributing to treatment resistance.
- * They proposed a new approach that targets MALT1, a key partner in the resistance pathway, which shows potential for overcoming resistance and improving treatment outcomes in MCL, even in the presence of resistance mutations.
Article Synopsis
- CPX-351, a drug combining cytarabine and daunorubicin, shows better results than traditional treatments for secondary acute myeloid leukemia and is being tested for its safety and efficacy in related blood disorders.
- A phase 2 trial included patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia, focusing on those in their first-line treatment, while a second cohort was halted due to low patient enrollment.
- The trial's results indicated a strong response rate, with 87% of participants showing improvement after treatment with CPX-351, backed by data collected from 31 patients during the study period.
Article Synopsis
- Immunotherapy that uses the body's immune system is becoming popular in treating blood cancers like mantle cell lymphoma (MCL), but there's little understanding of immune cell behavior in MCL patients' lymph nodes and bone marrow.
- The study utilized a technique called RT-MLPA to analyze gene expression in MCL patients at diagnosis and relapse, focusing on immune-related genes to gain insights into tumor aggressiveness and immune response.
- Results showed that aggressive MCL forms had increased macrophage-related gene expression but lower T-cell markers, which could help differentiate between patient groups and guide personalized treatment approaches.
Article Synopsis
- Next-generation sequencing (NGS) is being evaluated for its role in detecting somatic mutations in patients with chronic myeloid malignancies, but its effectiveness in routine clinical decision-making is still uncertain.
- In a multicenter study involving 177 patients, two groups were examined: one focused on identifying clonal hematopoiesis and the other on assessing therapeutic effects of somatic mutations using a specific gene panel.
- The results indicated that NGS significantly aided in making accurate diagnoses for 83% of patients and led to treatment modifications in 19%, highlighting its potential benefits for patient management and healthcare costs.
We report five chronic myeloid leukaemia (CML) patients in whom we identified and characterized undescribed BCR-ABL1 fusion transcripts. We investigated the precise features of the molecular rearrangements and the minimal residual disease follow-up for these five patients. Three resulted from new rearrangements between the BCR and ABL1 sequences (the breakpoints being located within BCR exon 13 in two cases and within BCR exon 18 in one case).
View Article and Find Full Text PDFAlthough targeted therapies are used increasingly in hematologic malignancies, we are unaware of any prior studies of radioimmunotherapy (RAIT) in B-acute lymphoblastic leukemia (ALL), even though this radiosensitive tumor expresses CD22, potentially a good target for this approach. Here, we report a patient with Philadelphia chromosome-positive B-ALL in third relapse who received RAIT with (90) yttrium ((90) Y)-labeled anti-CD22 epratuzumab tetraxetan. Seven weeks after initiating therapy, the patient achieved a BCR-ABL1 molecular remission documented by RT-qPCR, which is now continuing at 6 months while awaiting an allogeneic hematopoietic stem cell transplant.
View Article and Find Full Text PDF